TABLE 3.
Laboratory results and clinical features at baseline/time of HPE
| CMV positive (n= 29) | CMV negative (n = 220) | p | |
|---|---|---|---|
| Age at HPE (d) [mean (SD)] | 67.8 ± 13.6 | 55.1 ± 18.5 | 0.0005 |
| Liver biopsy fibrosis staginga [n (%)] | 16 (55) | 134 (61) | 0.56 |
| Stage 0 | 0 | 3 (2) | |
| Stage 1 | 0 | 11 (8) | |
| Stage 2 | 5 (31) | 39 (29) | |
| Stage 3 | 7 (44) | 48 (36) | |
| Stage 4 | 1 (6) | 16 (12) | |
| Stage 5 | 1 (6) | 13 (10) | |
| Stage 6 | 2 (13) | 4 (3) | |
| Albuminb (g/dL) | 3.7 (2.6–4.3) | 3.6 (1.7–5.7) | 0.23 |
| Alkaline phosphataseb (U/L) | 617 (332–1804) | 466 (95–1190) | 0.001 |
| ALTb (U/L) | 164 (16–522) | 109 (11–890) | 0.01 |
| ASTb (U/L) | 233 (63–738) | 169 (39–1777) | 0.001 |
| Bilirubin (total)b (mg/dL) | 7.6 (4.2–15) | 8.3 (1.1–19.8) | 0.91 |
| Bilirubin (direct)b (mg/dL) | 5.3 (2.6–11) | 5.6 (1.4–12) | 0.99 |
| GGTb (U/L) | 738 (130–2491) | 544 (60–3087) | 0.15 |
| INRb | 1.1 (0.9–6.9) | 1.0 (0.8–8.0) | <0.001 |
| Plateletsb (×103/μL) | 420 (220–818) | 460 (28–1160) | 0.43 |
| WBCb (×103/μL) | 12.5 (5.7–31.1) | 12.9 (4.1–611.5) | 0.74 |
| APRib | 1.2 (0.5–5.0) | 0.9 (0.2–15.8) | <0.001 |
Note: Bolded values are those that are statistically significant.
a
Per Ishak grading.
b
Laboratory values presented as median (range).
Abbreviations: ALT, alanine aminotransferase; APRi, AST-to-platelet ratio index; AST, aspartate aminotransferase; CMV, cytomegalovirus; GGT, gamma-glutamyl transpeptidase; HPE, hepatic portoenterostomy; INR, international normalized ratio; WBC, white blood count.